KRAS and familial pancreatic carcinoma: We next evaluated the effects of ORP8 knockdown on KRAS and PtdSer localization in a panel of pancreatic cancer cell lines that are wild-type for KRAS, such as BxPC-3, or contain a KRAS mutation, such as PANC-1, MiaPaCa-2, and MOH.